NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2026)
NewAmsterdam Pharma (NAMS) recorded EBITDA Margin of -1751.01% in Q2 2026, down 1565.12 percentage points from -185.90% a year earlier but up 168.66 percentage points from the prior quarter.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2026) Analysis & Trends
On a TTM basis, NewAmsterdam Pharma's EBITDA Margin came in at -3428.77% as of Jun 30, 2026, down 3159.09 percentage points year-over-year; for FY2025, it was -1001.92%, down 615.26 percentage points from FY2024.
- Annual EBITDA Margin has a three-year change of -932.66 percentage points (FY2022 to FY2025).
- Across earlier years, EBITDA Margin came in at -386.66% in FY2024 (+911.55 pp), -1298.21% in FY2023 (-1228.95 pp) and -69.26% in FY2022.
- Quarterly EBITDA Margin has ranged from -206003.13% in Q4 2025 to -85.79% in Q3 2024 over the past five years.
- On a year-over-year basis, EBITDA Margin rose in five of the last eight quarters, with an average year-over-year change of -26399.07 percentage points.
- Peak year-over-year performance for EBITDA Margin in the last five years was a gain of 6020.71 percentage points in Q4 2024, against a drop of 205665.06 percentage points in Q4 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at -1919.67% (Q1 2026), -206003.13% (Q4 2025) and -15827.30% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 39.10% |
| 10 | NewAmsterdam Pharma | 2.77 Bn | 2.77 Bn | - | -1,751.01% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,751.01% |
| Mar 31, 2026 | -1,919.67% |
| Dec 31, 2025 | -206,003.13% |
| Sep 30, 2025 | -15,827.30% |
| Jun 30, 2025 | -185.90% |
| Mar 31, 2025 | -2,312.73% |
| Dec 31, 2024 | -338.07% |
| Sep 30, 2024 | -85.79% |
| Jun 30, 2024 | -2,306.10% |
| Mar 31, 2024 | -3,959.10% |
| Dec 31, 2023 | -6,358.78% |
| Sep 30, 2023 | -1,684.60% |
| Jun 30, 2023 | -2,473.44% |
| Mar 31, 2023 | -461.75% |
API Access
NewAmsterdam Pharma EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NAMS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "NAMS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NAMS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();